Loading...
Docoh

RVL Pharmaceuticals (RVLP)

News

From Benzinga Pro
RVL Pharmaceuticals: Q1 Earnings Insights
12 May 22
Earnings, News
RVL Pharmaceuticals (NASDAQ:RVLP) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:50 AM. Here's what investors need to know about the announcement.
RVL Pharmaceuticals plc - Ordinary Shares Q1 EPS $(0.08) Beats $(0.21) Estimate, Sales $21.40M Beat $7.44M Estimate
12 May 22
Earnings, News
RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.21) by 61.9 percent. This is a 46.67 percent increase over losses of
Earnings Scheduled For May 12, 2022
12 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
RVL Pharmaceuticals plc - Ordinary Shares's Earnings: A Preview
11 May 22
Earnings
RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement.
RVL Pharmaceuticals plc - Ordinary Shares's Return On Capital Employed Insights
31 Mar 22
Earnings
Benzinga Pro data, RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) reported Q4 sales of $2.86 million. Earnings fell to a loss of $19.72 million, resulting in a 10.43% decrease from last quarter.
RVL Pharmaceuticals plc - Ordinary Shares Q4 EPS $(0.24) Beats $(0.27) Estimate
30 Mar 22
Earnings, News
RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 72.73 percent increase over losses
Earnings Scheduled For March 30, 2022
30 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021.
RVL Pharmaceuticals plc - Ordinary Shares's Earnings: A Preview
29 Mar 22
Earnings
RVL Pharmaceuticals plc - Ordinary Shares (NASDAQ:RVLP) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
27 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, Trading Ideas, General
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
12 Health Care Stocks Moving In Friday's After-Market Session
18 Mar 22
Movers
Gainers

Press releases

From Benzinga Pro
RVL Pharmaceuticals plc to Present at Upcoming Conferences
16 May 22
News, Health Care, Press Releases
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will
RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update
12 May 22
Earnings, Press Releases
First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related
UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards"
9 May 22
Press Releases
BRIDGEWATER, N.J., May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company") announced today that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride
RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update
5 May 22
Press Releases
BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its first quarter
UPNEEQ® Wins "Best in Innovation" Award from New Beauty
6 Apr 22
Press Releases
12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (NASDAQ:RVLP) announced today that its U.S. FDA approved acquired blepharoptosis
RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results
6 Apr 22
Health Care, Press Releases
-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidance of $20 to 25
RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ® Revenue Estimate and Business Update
30 Mar 22
Earnings, Press Releases
Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million, respectively Full national
RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022 Update on Medical Aesthetic Launch
23 Mar 22
News, Health Care, Press Releases
BRIDGEWATER, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 fourth
RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022
9 Mar 22
News, Press Releases
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer,